{"nctId":"NCT00978068","briefTitle":"HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children","startDateStruct":{"date":"2009-09"},"conditions":["Malaria","HIV Infections"],"count":176,"armGroups":[{"label":"Lopinavir/ritonavir (LPV/r) +2 NRTI","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Lopinavir/Ritonavir (LPV/r)","Drug: 2 nucleoside reverse transcriptase inhibitor (NRTI)"]},{"label":"Nevirapine (NVP) or Efavirenz (EFV) +2 NRTI","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Nevirapine (NVP)","Drug: Efavirenz (EFV)","Drug: 2 nucleoside reverse transcriptase inhibitor (NRTI)"]}],"interventions":[{"name":"Lopinavir/Ritonavir (LPV/r)","otherNames":["Aluvia"]},{"name":"Nevirapine (NVP)","otherNames":[]},{"name":"Efavirenz (EFV)","otherNames":[]},{"name":"2 nucleoside reverse transcriptase inhibitor (NRTI)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n1. Age 2 months to \\< 11 years\n2. Confirmed HIV diagnosis. i. Children \\> 18 months: Documentation of HIV status must come from two assays. Assays include DNA PCR, HIV RNA, Western blot, or rapid HIV antibody test ii. Children \\< 18 months: Documentation will be DNA PCR confirmation only along with documentation of testing from the referral entity\n3. ART-naïve patients eligible for ART initiation per WHO/Uganda guidelines (see Table 1) or Patients receiving first line ART regimen with NNRTI +2 NRTI with at least one HIV RNA \\<400 copies/ml within the past 6 months\n4. Agreement to come to the study clinic for any febrile episode or other illness\n5. Agreement to avoid medications administered outside study protocol\n6. Provision of informed consent by parent/guardian and agreement to have child's care at the clinical site\n7. Lives within 50 km of study site\n\nExclusion criteria:\n\n1. ART-naïve children: children or their mothers that have received any dose of Nevirapine in the past 24 months\n2. Active medical problem requiring in-patient evaluation at the time of screening or enrollment\n3. History of cardiac conduction disorder or known significant cardiac structural defect\n4. Children receiving any disallowed medications (see section 4.3)\n5. Moderate, Severe or Life-threatening (Grade 2, 3, or 4) AST or ALT found within 4 weeks prior to enrollment:\n\n   * AST: \\>113U/L (\\>2.5xULN)\n   * ALT: \\>113U/L (\\>2.5xULN)\n6. Life-threatening (Grade 4) screening laboratory value found within 4 weeks prior to enrollment for the following:\n\n   * Absolute neutrophil count: \\<500 mm3\n   * Hemoglobin: \\<6.5 g/dL\n   * Creatinine: \\>3.5xULN\n   * Platelets: \\<25,000/mm3","healthyVolunteers":true,"sex":"ALL","minimumAge":"2 Months","maximumAge":"10 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence-density of Malaria Defined as the Number of Incident Episodes of Malaria Per Time at Risk.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.32","spread":null},{"groupId":"OG001","value":"2.25","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Uncomplicated Malaria Episodes With Accompanying Adverse Events That Occurred in the 28 Days Following Antimalarial Therapy","description":"The rates of adverse events, defined as severity grade 2 or higher that are possibly, probably or definitely related to study drugs over the course of the 28-day period after antimalarial therapy with artemether-lumefantrine (AL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.0","spread":null},{"groupId":"OG001","value":"79.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence-density of Malaria Defined as the Number of Incident Episodes of Complicated Malaria Per Time at Risk.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.024","spread":null},{"groupId":"OG001","value":"0.026","spread":null}]}]}]},{"type":"SECONDARY","title":"Estimates of the 6-month Risk of a First Episode of Malaria","description":"To assess the effect of ART independently of potential interactions with antimalarial therapy after treatment for malaria, we compared the two groups with respect to the time to the first episode of malaria. Cumulative risk was estimated using the Kaplan-Meier product-limit formula.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.7","spread":null},{"groupId":"OG001","value":"52.5","spread":null}]}]}]},{"type":"SECONDARY","title":"28-day Risk of Recurrent Parasitemia","description":"To assess the effect of potential interactions between ART and artemether-lumefantrine, the risks of recurrent parasitemia at 28 days were compared between the two groups.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.0","spread":null},{"groupId":"OG001","value":"40.8","spread":null}]}]}]},{"type":"SECONDARY","title":"63-day Risk of Recurrent Malaria","description":"To assess the effect of potential interactions between ART and artemether-lumefantrine, the risks of recurrent malaria at 63 days were compared between the two groups.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.1","spread":null},{"groupId":"OG001","value":"54.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":84},"commonTop":["Neutropenia","Elevated Temperature","Thrombocytopenia Platelets, decreased","Anemia","Elevated ALT"]}}}